---
title: >-
  Safety and Effectiveness of Tenofovir Alafenamide in Usual Clinical Practice
  Confirms Results of Clinical Trials: TARGET-HBV.
description: >-
  Explore this publication on real-world evidence: Safety and Effectiveness of
  Tenofovir Alafenamide in Usual Clinical Practice Confirms Results of Clinical…
date: '2021-01-01'
category: Publications
tags:
  - Digestive Diseases And Sciences
  - Abstract / Manuscript
  - R&D
  - Care
  - Hepatology
  - HBV
  - Health System Partner
canonical_url: >-
  https://www.pedestalhealth.com/resources/publications/digestive-diseases-and-sciences/safety-and-effectiveness-of-tenofovir-alafenamide-in-usual/
source: Pedestal Health
license: © 2026 Pedestal Health. All rights reserved.
slug: safety-and-effectiveness-of-tenofovir-alafenamide-in-usual
id: 2qH5w1O8IDCTlPMMHMEI8K
contentType: article
---

## Challenge

TAF was approved for chronic hepatitis B in 2016 based on clinical trial data, but its safety and effectiveness in the more heterogeneous US real-world population—including patients previously treated with other antivirals and those with more advanced liver disease—had not been established post-authorization.

## Solution

The TARGET-HBV longitudinal cohort was used to characterize the clinical outcomes of 500 TAF-treated patients in usual clinical practice across academic and community US sites, comparing effectiveness and safety signals against the registration trial (POISE) population.

## Impact

Confirming that TAF achieves comparable virological suppression and safety outcomes in a broader, more advanced real-world population validates the generalizability of registration trial results and provides the post-authorization effectiveness evidence required for prescriber confidence and payer negotiations.

### [Andrea R. Mospan](/people/andrea-mospan/)

![Andrea R. Mospan, PhD, RAC — Profile Photo](https://images.ctfassets.net/h4s3ip99qawo/4w6bkwPHPqrXKYs4tHZPkK/1d21763b54ecc3466764986693b7072f/andrea-mospan.jpg)